Long-term follow-up data indicate that on-target off-tumor toxicity, leading to B-cell aplasia and hypogammaglobulinemia, are the most common long-term adverse reactions following treatment with anti-CD19 CAR-T cells (14). The gene discussed is CD19; the disease is neoplasm.